First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?

Seddon Beatrice

首页> 外文期刊>Current Opinion in Oncology >First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?

【24h】

First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?

机译：晚期或转移性疾病的一线治疗：一种尺寸适合所有患者或适合特定的组织型吗？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose of review

机译：审查目的

著录项

来源
《Current Opinion in Oncology》 |2016年第4期|共8页
作者
Seddon Beatrice;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
advanced metastatic; chemotherapy; first line; histiotype; soft tissue sarcoma;

机译：晚期转移;化学疗法;一线;组织型;软组织肉瘤;

相似文献

外文文献
中文文献
专利

1. First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes? [J] . Seddon Beatrice Current Opinion in Oncology . 2016,第4期

机译：晚期或转移性疾病的一线治疗：一种尺寸适合所有患者或适合特定的组织型吗？
2. Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation [J] . Douglas R., Campbell L., McAleese J., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2013,第Suppla1期

机译：吉非替尼用于一线治疗EGFR突变患者的局部晚期或转移性非小细胞肺癌的审计
3. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. [J] . Brown T, Boland A, Bagust A, Health technology assessment: HTA . 2010,第Suppla2期

机译：吉非替尼用于一线治疗局部晚期或转移性非小细胞肺癌。
4. Is High-Dose Chemotherapy Plus Stem-Cell Transplant the Standard Treatment for Patients Failing First-Line Chemotherapy for Metastatic Germ Cell Tumor? [C] . Christian Kollmannsberger, Lawrence Einhorn, Craig Nichols Genitourinary Cancers Symposium. . 2014

机译：高剂量化疗加干细胞移植对转移细胞肿瘤的一线化疗失败的患者的标准治疗吗？
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer [O] . Longfeng Zhang, Na Li, Maobai Liu, 2021

机译：Dacomitinib对吉非替尼的成本效果分析在初级治疗EGFR阳性晚期或转移性非小细胞肺癌中
7. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study [O] . Yang James Chih-Hsin, Srimuninnimit Vichien, Ahn Myung-Ju, 2016

机译：一线培美曲塞加顺铂再加吉非替尼维持治疗与吉非替尼单药治疗在患有局部晚期或转移性非鳞状非小细胞肺癌的东亚非吸烟患者中：一项随机第3期研究的最终总生存率

First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?

摘要

著录项

相似文献

相关主题

期刊订阅